Study of valproic acid-induced endogenous and exogenous metabolite alterations using LC-MS-based metabolomics

Bioanalysis

Volumn 2, Issue 2, 2010, Pages 207-216

  Sun, Jinchun ^a   Schnackenberg, Laura K ^a   Hansen, Deborah K ^a   Beger, Richard D ^a  

^a NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; VALPROIC ACID; VALPROIC ACID DERIVATIVE; AMINO ACID; ANTICONVULSIVE AGENT;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DISEASE MARKER; DRUG URINE LEVEL; FEMALE; KIDNEY FUNCTION; LIQUID CHROMATOGRAPHY; LIVER TOXICITY; MASS SPECTROMETRY; METABOLITE; METABOLOMICS; MOUSE; NEPHROTOXICITY; NONHUMAN; PRINCIPAL COMPONENT ANALYSIS; ANIMAL; METABOLISM; METHODOLOGY; URINE;

AMINO ACIDS; ANIMALS; ANTICONVULSANTS; BIOLOGICAL MARKERS; CHROMATOGRAPHY, LIQUID; FEMALE; MASS SPECTROMETRY; METABOLOMICS; MICE; VALPROIC ACID;

EID: 79952514795     PISSN: 17576180     EISSN: 17576199     Source Type: Journal    
DOI: 10.4155/bio.09.173     Document Type: Article

References (41)

1. Swann AC, Bowden CL, Morris D, et al. Depression during mania. Treatment response to lithium or divalproex. Arch. Gen. Psychiatry 54, 37-42 (1997). (Pubitemid 27044696)
2. Costello LE, Suppes T. A clinically significant interaction between clozapine and valproate. J. Clin. Psychopharmacol. 15, 139-41 (1995).
3. Eadie MJ, McKinnon GE, Dunstan PR, MacLaughlin D, Dickinson RG. Valproate metabolism during hepatotoxicity associated with the drug. Q. J. Med. 77(284), 1229-1240 (1990).
4. Bryant AE 3rd, Dreifuss FE. Valproic acid hepatic fatalities. III. US experience since 1986. Neurology 46, 465-469 (1996). (Pubitemid 26081333)
5. Gerber N, Dickinson RG, Harland RC, et al. Reye-like syndrome associated with valproic acid therapy. J. Pediatr. 95, 142-144 (1979). (Pubitemid 9183702)
6. Watson WA, Litovitz TL, Rodgers GCJ, et al. 2002 annual report of the American association of poison control centers toxic exposure surveillance system. Am. J. Emerg. Med. 21, 353-421 (2003).
7. Korinthenberg R, Wehrle L, Zimmerhackl LB. Renal tubular dysfunction following treatment with anti-epileptic drugs. Eur. J. Pediatr. 153, 855-858 (1994). (Pubitemid 24314760)
8. Unay B, Akin R, Sarici SU, Gok F, Kurt I, Gokcay E. Evaluation of renal tubular function in children taking anti-epileptic treatment. Nephrology (Carlton) 11, 485-488 (2006). (Pubitemid 44951226)
9. Al Aly Z, Yalamanchili P, Gonzalez E. Extracorporeal management of valproic acid toxicity: a case report and review of the literature. Semin Dial. 18, 62-626 (2005).
10. Zimmerman HJ, Ishak KG. Valproate-induced hepatic injury: analyses of 23 fatal cases. Hepatology 2, 591-597 (1982). (Pubitemid 13173942)
11. Abbott FS, Anari MR. Chemistry and biotransformation. In: Valproate. Milestones in Drug Therapy. Birkhäuser Verlag, Basel, Switzerland. 47-75 (1999).
12. Granneman GR, Wang SI, Machinist JM, Kesterson JW. Aspects of the metabolism of valproic acid. Xenobiotica 14, 375-387 (1984). (Pubitemid 14083611)
13. Robertson DG. Metabonomics in toxicology: a review. Toxicol. Sci. 85, 809-822 (2005). (Pubitemid 40846857)
14. Nicholson JK, Wilson ID. Opinion: understanding 'global' systems biology: metabonomics and the continuum of metabolism. Nat. Rev. Drug Discov. 2, 668-676 (2003). (Pubitemid 37361770)
15. Sanders M, Shipkova PA, Zhang H, Warrack BM. Utility of the hybrid LTQ-FTMS for drug metabolism applications. Curr. Drug Metab. 7, 547-555 (2006).
16. Plumb RS, Stumpf CL, Granger JH, Castro-Perez J, Haselden JN, Dear GJ. Use of liquid chromatography/time-of-flight mass spectrometry and multivariate statistical analysis shows promise for the detection of drug metabolites in biological fluids. Rapid Commun. Mass Spectrom. 17, 2632-2638 (2003). (Pubitemid 37498776)
17. Raff AC, Meyer TW, Hostetter TH. New insights into uremic toxicity. Curr. Opin. Nephrol. Hypertens. 17, 560-565 (2008).
18. Atoh K, Itoh H, Haneda M. Serum indoxyl sulfate levels in patients with diabetic nephropathy: relation to renal function. Diabetes Res. Clin. Pract. 83, 220-226 (2009).
19. Gopaul VS, Tang W, Farrell K, Abbott FS. Amino acid conjugates: metabolites of 2-propylpentanoic acid (valproic acid) in epileptic patients. Drug Metab. Dispos. 31, 114-121 (2003). (Pubitemid 36735265)
20. Turnbull DM, Bone AJ, Bartlett K, Koundakjian PP, Sherratt HS. The effects of valproate on intermediary metabolism in isolated rat hepatocytes and intact rats. Biochem. Pharmacol. 32, 1887-1892 (1983). (Pubitemid 13067966)
21. MSI Board Members, Sansone SA, Fan T, et al. The metabolomics standards iniative (MSI). Nat. Biotechnol. 25, 846-848 (2007).
22. Rainville PD, Stumpf CL, Shockcor JP, Plumb RS, Nicholson JK. Novel application of reversed-phase UPLC-oaTOF-MS for lipid analysis in complex biological mixtures: a new tool for lipidomics. J. Proteome Res. 6, 552-558 (2007). (Pubitemid 46340159)
23. Tang W, Abbott FS. A comparative investigation of 2-propyl-4-pentenoic acid (4-ene VPA) and its a-fluorinated analogue: phase II metabolism and pharmacokinetics. Drug Metab. Dispos. 25, 219-227 (1997). (Pubitemid 27086123)
24. Kassahun K, Farrell K, Abbott F. Identification and characterization of the glutathione and N-acetylcysteine conjugates of (E)-2-propyl-2,4-pentadienoic acid, a toxic metabolite of valproic acid, in rats and humans. Drug Metab. Dispos. 19, 525-535 (1991).
25. Reed DJ. Glutathione: toxicological implications. Annu. Rev. Pharmacol. Toxicol. 30, 603-631 (1990).
26. Baillie TA. Metabolic activation of valproic acid and drug-mediated hepatotoxicity. Role of the terminal olefin, 2-N-propyl-4-pentenoic acid. Chem. Res. Toxicol. 1, 195-199 (1988).
27. Harris RA, Swartzentruber M, Becker CM, AcCune SA, Hu H, Popov K. Metabolic effects of sequestration of hepatic mitochondrial coenzyme A by valproate and other carboxylic acids. In: Idiosyncratic Reactions to Valproate: Clinical Risk Patterns and Mechanisms of Toxicity. Levy RH, Penry JK (Eds). Raven Press, NY, USA, 97 (1991).
28. Rios LY, Gonthier MP, Rémésy C, et al. Chocolate intake increases urinary excretion of polyphenol-derived phenolic acids in healthy human subjects. Am. J. Clin. Nutr. 77, 912-918 (2003).
29. Zaki EL, Springate JE. Renal injury from valproic acid: case report and literature review. Pediatr. Neurol. 27, 318-319 (2002). (Pubitemid 35341708)
30. Rahman MH, Haqqie SS, McGoldrick MD. Acute hemolysis with acute renal failure in a patient with valproic acid poisoning treated with charcoal hemoperfusion. Hemodial. Int. 10, 256-259 (2006). (Pubitemid 43923208)
31. Foreman J. Cystinosis and Fanconi syndrome. In: Pediatric Nephrology. Barratt T, Avner E, Harmon W (Eds). Lippincott Williams and Wilkins, MD, USA, 593-605 (1999).
32. Schnackenberg LK, Jones RC, Thyparambil S, et al. An integrated study of acute effects of valproic acid in the liver using metabonomics, proteomics, and transcriptomics platforms. OMICS 10, 1-14 (2006).
33. Beger RD, Hansen DK, Schnackenberg LK, et al. Single valproic acid treatment inhibits glycogen and RNA ribose turnover while disrupts glucose-derived cholesterol synthesis in liver as revealed by the [U-13C6]-d-glucose tracer in mice. Metabolomics 5, 336-345 (2009).
34. Atoh K, Itoh H, Haneda M. Serum indoxyl sulfate levels in patients with diabetic nephropathy: relation to renal function. Diabetes Res. Clin. Pract. 83, 220-226 (2009).
35. Niwa T, Aoyama I, Takayama F, et al. Urinary indoxyl sulfate is a clinical factor that affects the progression of renal failure. Miner. Electrolyte Metab. 25, 118-122 (1999). (Pubitemid 29196647)
36. Valentovic MA, Lo HH, Brown PI, Rankin GO. 3,5-dichloroaniline toxicity in Fischer 344 rats pretreated with inhibitors and inducers of cytochrome P450. Toxicol. Lett. 78, 207-214 (1995).
37. Rankin GO, Yang DJ, Teets VJ, Lo HH, Brown PI. 3,5-dichloroaniline- induced nephrotoxicity in the Sprague-Dawley rat. Toxicol. Lett. 30, 173-179 (1986).
38. Clayton TA, Lindon JC, Everett JR, et al. Hepatotoxin-induced hypercreatinaemia and hypercreatinuria: their relationship to one another, to liver damage and to weakened nutritional status. Arch. Toxicol. 78, 86-96 (2004). (Pubitemid 38316663)
39. Clayton TA, Lindon JC, Everett JR, et al. An hypothesis for a mechanism underlying hepatotoxin-induced hypercreatinuria. Arch. Toxicol. 77, 208-217 (2003). (Pubitemid 36583783)
40. Schnackenberg LK, Chen M, Sun J, et al. Evaluations of the trans-sulfuration pathway in multiple liver toxicity studies. Toxicol. Appl. Pharmacol. 235(1), 25-32 (2008).
41. Espandiari P, Zhang J, Schnackenberg LK, et al. Age-related differences in susceptibility to toxic effects of valproic acid in rats. J. Appl. Toxicol. 28, 628-637 (2008). (Pubitemid 352009753)